Adynxx (ADYX) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 10, 2019
Document Information [Line Items]
Entity Registrant Name	Adynxx, Inc.
Entity Central Index Key	0001054274
Trading Symbol	adyx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		5,807,877
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 24,000	$ 1,887,000
Restricted cash	254,000	55,000
Prepaid expenses and other current assets	1,622,000	10,000
Total current assets	1,900,000	1,952,000
Property and equipment, net	6,000	10,000
Right of use asset, net	779,000
Other assets	18,000	18,000
Total assets	2,703,000	1,980,000
Current liabilities
Accounts payable	1,748,000	491,000
Accrued liabilities	1,480,000	857,000
Current portion of operating lease liability	346,000
Convertible promissory notes - related party	5,497,000	4,500,000
Current portion of term loan, net of discount	2,390,000	3,812,000
Total current liabilities	11,461,000	9,660,000
Operating lease liability, net of current portion	493,000
Warrant liability		140,000
Commitments and contingencies (Note 7)
Stockholders' deficit
Preferred stock, $0.001 par value; 1,000,000 shares authorized no shares issued or outstanding
Common stock, $0.001 par value; 95,000,000 shares authorized, 5,807,877 shares issued and outstanding at June 30, 2019 (unaudited) 5,313,200 shares authorized, 701,808 shares issued and outstanding at December 31, 2018	6,000	1,000
Additional paid-in capital	35,160,000	747,000
Accumulated deficit	(44,417,000)	(37,279,000)
Total stockholders' deficit	(9,251,000)	(36,531,000)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	2,703,000	1,980,000
Series A Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		12,814,000
Series B Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		$ 15,897,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	95,000,000	5,313,200
Common stock, shares issued (in shares)	5,807,877	701,808
Common stock, shares outstanding (in shares)	5,807,877	701,808
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 1	$ 1
Redeemable convertible preferred stock, shares authorized (in shares)	0	2,046,378
Redeemable convertible preferred stock, shares issued (in shares)	0	2,034,548
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 0.001	$ 0.001
Redeemable convertible preferred stock, shares authorized (in shares)	0	1,833,387
Redeemable convertible preferred stock, shares issued (in shares)	0	1,833,387

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating expenses
Research and development	$ 1,895	$ 583	$ 3,226	$ 1,269
General and administrative	1,454	598	2,317	1,292
Grant reimbursements	(1,104)		(1,198)
Total operating expenses, net	2,245	1,181	4,345	2,561
Loss from operations	(2,245)	(1,181)	(4,345)	(2,561)
Interest expense, net	(2,373)	(301)	(2,641)	(445)
Other income (expense), net		60	(94)	60
Loss from continuing operations	(4,618)	(1,422)	(7,080)	(2,946)
Loss from discontinued operations	(58)		(58)
Net loss	$ (4,676)	$ (1,422)	$ (7,138)	$ (2,946)
Net loss per basic and diluted share:
Loss from continuing operations (in dollars per share)	$ (0.86)	$ (0.31)	$ (1.43)	$ (0.64)
Loss from discontinued operations (in dollars per share)	(0.01)		(0.01)
Net loss per basic and diluted share (in dollars per share)	$ (0.87)	$ (0.31)	$ (1.44)	$ (0.64)
Weighted-average number of common shares outstanding - basic and diluted (in shares)	5,358,882	4,569,742	4,966,491	4,569,742

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]Series A Redeemable Convertible Preferred Stock [Member]	Preferred Stock [Member]Series B Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	2,034,548	1,833,387	701,808
Balance at Dec. 31, 2017	$ 12,814	$ 15,897	$ 1	$ 438	$ (31,294)	$ (30,855)
Stock-based compensation expense				75		75
Net loss					(1,523)	(1,523)
Balance (in shares) at Mar. 31, 2018	2,034,548	1,833,387	701,808
Balance at Mar. 31, 2018	$ 12,814	$ 15,897	$ 1	513	(32,817)	(32,303)
Balance (in shares) at Dec. 31, 2017	2,034,548	1,833,387	701,808
Balance at Dec. 31, 2017	$ 12,814	$ 15,897	$ 1	438	(31,294)	(30,855)
Net loss						(2,946)
Balance (in shares) at Jun. 30, 2018	2,034,548	1,833,387	701,808
Balance at Jun. 30, 2018	$ 12,814	$ 15,897	$ 1	588	(34,239)	(33,650)
Balance (in shares) at Mar. 31, 2018	2,034,548	1,833,387	701,808
Balance at Mar. 31, 2018	$ 12,814	$ 15,897	$ 1	513	(32,817)	(32,303)
Stock-based compensation expense				75		75
Net loss					(1,422)	(1,422)
Balance (in shares) at Jun. 30, 2018	2,034,548	1,833,387	701,808
Balance at Jun. 30, 2018	$ 12,814	$ 15,897	$ 1	588	(34,239)	(33,650)
Balance (in shares) at Dec. 31, 2018	2,034,548	1,833,387	701,808
Balance at Dec. 31, 2018	$ 12,814	$ 15,897	$ 1	747	(37,279)	(36,531)
Stock-based compensation expense				84		84
Net loss					(2,462)	(2,462)
Balance (in shares) at Mar. 31, 2019	2,034,548	1,833,387	701,808
Balance at Mar. 31, 2019	$ 12,814	$ 15,897	$ 1	831	(39,741)	(38,909)
Balance (in shares) at Dec. 31, 2018	2,034,548	1,833,387	701,808
Balance at Dec. 31, 2018	$ 12,814	$ 15,897	$ 1	747	(37,279)	(36,531)
Net loss						(7,138)
Balance (in shares) at Jun. 30, 2019			5,807,877
Balance at Jun. 30, 2019			$ 6	35,160	(44,417)	(9,251)
Balance (in shares) at Mar. 31, 2019	2,034,548	1,833,387	701,808
Balance at Mar. 31, 2019	$ 12,814	$ 15,897	$ 1	831	(39,741)	(38,909)
Stock-based compensation expense				84		84
Net loss					(4,676)	(4,676)
Conversion of convertible notes into convertible preferred stock (in shares)		(367,041)
Conversion of convertible notes into convertible preferred stock		$ 3,203
Recognition of beneficial conversion feature upon conversion of convertible notes		$ 2,101
Conversion of of convertible preferred stock into common stock (in shares)	(2,034,548)	(2,200,428)	4,234,976
Conversion of of convertible preferred stock into common stock	$ (12,814)	$ (21,201)	$ 4	34,011		34,015
Issuance of common stock for merger (in shares)			854,017
Issuance of common stock for merger			$ 1	1		2
Equity issuance costs paid in stock (in shares)			17,076
Equity issuance costs paid in stock
Impact of change of warrants subject to fair value measure to equity warrants				234		234
Spin-off of AquaMed				(1)		(1)
Balance (in shares) at Jun. 30, 2019			5,807,877
Balance at Jun. 30, 2019			$ 6	$ 35,160	$ (44,417)	$ (9,251)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (7,138,000)	$ (2,946,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	4,000	4,000
Stock-based compensation expense	168,000	150,000
Changes in fair value of warrant liability	95,000	1,000
Changes in fair value of derivative liability		(60,000)
Accretion of final charge upon maturity of Oxford Term Loan A and B	148,000	94,000
Amortization of issuance cost and discounts for term loans and convertible notes	16,000	130,000
Non-cash interest expense on convertible promissory notes	2,304,000	31,000
Non-cash operating lease cost	140,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,611,000)	(12,000)
Other assets	57,000
Accounts payable	1,255,000	(607,000)
Accrued liabilities	475,000	(312,000)
Lease liability	(136,000)
Net cash used in operating activities	(4,223,000)	(3,527,000)
Cash flows from investing activities:
Net cash used in investing activities
Cash flows from financing activities:
Payments on term loan	(1,437,000)	(616,000)
Proceeds from issuance of convertible promissory notes - related party	3,996,000	1,500,000
Net cash provided by financing activities	2,559,000	884,000
Net decrease in cash, cash equivalents and restricted cash	(1,664,000)	(2,643,000)
Cash, cash equivalents and restricted cash at beginning of period	1,942,000	4,356,000
Cash, cash equivalents and restricted cash at end of period	278,000	1,713,000
Other supplemental disclosure:
Cash paid for interest	173,000	190,000
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease obligations(1)	227,000
Reclassification of warrant liability to paid in capital	234,000
Conversion of convertible preferred stock into common stock	$ 34,015,000

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1. The Company On May 3, 2019, ‘Note 3 The Company is a clinical stage biopharmaceutical company focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company is primarily engaged in developing initial product technology, recruiting personnel, and raising capital. Basis of Presentation These unaudited financial statements represent the condensed consolidated financial statements of Adynxx and, for periods prior to the Merger, the condensed consolidated financial statements of Private Adynxx. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions of the SEC on Form 10 10 X not June 30, 2019 2018 not June 30, 2019 2018 8 June 10, 2019. All share and per share data for all periods presented have been retroactively restated to reflect the exchange ratio used in the Merger of 0.0359 1 6 May 3, 2019 The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management’s best knowledge of current events, historical experience, actions that the Company may may Liquidity The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As of June 30, 2019, $24,000 $3.0 $5.6 June 30, 2019, $44.4 not no In April 2019 May 2019, $2.0 $0.5 8% first ‘Note 6 The Company plans to finance its operations and capital funding needs through equity and/or debt financing. However, there can be no one The accompanying financial statements do not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company’s financial position and results of operations. Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company’s common stock and the valuation of the Company’s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one may not The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth. The Company’s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (“Avecia”) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no June 30, 2019, not At June 30, 2019, three 26%, 22% 17% 44% December 31, 2018, three 52%, 26% 15% 67% Clinical Trial Accruals The Company’s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company’s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations. Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not June 30, 2019 December 31, 2018, not Restricted Cash At June 30, 2019, $200,000 January 2019. June 30, 2019 December 31, 2018, $55,000 Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term— Expected Volatility— Expected Dividend— no Risk-Free Interest Rate— zero Research and Development Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (“CROs”), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred. Collaboration Agreement In June 2018, May 2019, $75,000, three six June 30, 2019. In June 2019, Grant Reimbursements In December 2018, two December 2020 $5.7 On January 1, 2019, 2018 08, may not For the three six June 30, 2019, $1,104,000 $1,198,000 Income Taxes The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return. Convertible Preferred Stock Warrants At December 31, 2018, no $234,000 three six June 30, 2019. Debt Modifications and Extinguishments When the Company modifies debt, it does so in accordance with Accounting Standards Codification (“ASC”) 470 50, Debt: Modifications and Extinguishments October 2018 March 2018 September 2018 $11,000 October 2018. not Derivative Instruments ASC 815 15, Derivatives and Hedging: Embedded Derivatives three three not not 815. At June 30, 2019 December 31, 2018, 1 2 These embedded features were not As of June 30, 2019 December 31, 2018, no ‘Note 6 Fair Value of Financial Instruments ASC 820 10, Fair Value Measurement three may Level 1— Level 2— 1 Level 3— This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. The following table presents the Company’s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December 31, 2018 ( As of December 31, 2018 Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ - $ - $ 140 $ 140 Total financial liabilities $ - $ - $ 140 $ 140 The Level 3 December 31, 2018 December 31, 2018, no three six June 30, 2019. The change in fair value of the warrant liability for the three six June 30, 2019 2018 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ 234 $ 42 $ 140 $ 42 Change in fair value of preferred stock warrants - - 94 - Exchange of warrants upon Merger (234 ) - (234 ) - Fair value at end of period $ - $ 42 $ - $ 42 The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company’s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. Derivative liability instruments are considered Level 3 one 3 no While the Company’s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero June 30, 2019 December 31, 2018. Note 6 The change in fair value of the derivative liability relating to the Notes for the three six June 30, 2019 2018 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ - $ 496 $ - $ - Embedded derivative liability from the issuance of Notes - - - 496 Change in value of embedded derivatives - (60 ) - (60 ) Fair value at end of period $ - $ 436 $ - $ 436 Discontinued Operations Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See ‘ Note 3 no June 30, 2019. Recently Adopted Accounting Pronouncements Lease Accounting In February 2016, No. 2016 02, 842 2016 02” 2016 02 twelve 2016 02 December 15, 2018 may 1 2 January 1, 2019 not The Company has elected the package of practical expedients permitted in ASC Topic 842. 842, 842, 842 The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not January 1, 2019 $227,000, $239,000, 9.41%, $227,000 $227,000. twelve January 1, 2019. Recent Accounting Pronouncements Not In August 2018, No. 2018 13, 820 December 15, 2019, In August 2018, 2018 15, 350 40 2018 15” not January 1, 2020

Note 3 - Reverse Merger

Note 3 - Reverse Merger	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Reverse Merger Disclosure [Text Block]	Note 3. Merger On May 3, 2019 368 1986, Subject to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of October 11, 2018, 0.0359 1 6 May 3, 2019 not may On May 3, 2019, $3.0 $203,000 367,041 Upon the completion of the Merger, Private Adynxx equity holders held 4,936,784 As described in “Spin-off” below, at the time of the Merger, Alliqua had in place a plan to spin-off all existing operations. Since Alliqua was deemed to have no not no Private Adynxx was determined to be the accounting acquirer based upon the terms of the Merger Agreement and other factors including: (i) Private Adynxx equity holders owned approximately 86% 14%; In connection with a previous modification of its Notes, the Company had computed a contingent beneficial conversion feature (“BCF”) that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470 20 25 6, not $2.1 three six June 30, 2019. Dividend In contemplation of the Merger, Alliqua declared a special cash dividend to the pre-Merger shareholders of Alliqua as of April 22, 2019. $5,245,000, $1.05 May 29, 2019. Spin-off On November 27, 2018, June 21, 2019. $0.01 Because the historical periods presented prior to the merger are those of Private Adynxx, the results of AquaMed are only reflected in these financial statements from the merger date to the date of the pro rata dividend of AquaMed and are presented as discontinued operations in the condensed consolidated statement of operations. Pro Forma Financial Information As the only significant operations of Alliqua have been discontinued with the spin-off transaction, pro forma financial information for periods prior to the merger is not not

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4. Property and equipment, net, consist of the following (in thousands): June 30, December 31, 2019 2018 Furniture and fixtures $ 29 $ 29 Office equipment 2 2 Computer equipment 18 18 Laboratory equipment 2 2 Total property and equipment 51 51 Less accumulated depreciation (45 ) (41 ) Property and equipment, net $ 6 $ 10 Depreciation expense for the three June 30, 2019 2018 $2,000 $2,000, six June 30, 2018 $4,000 $4,000

Note 5 - Other Balance Sheet In

Note 5 - Other Balance Sheet Information	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 5. Prepaid and other current assets consist of the following (in thousands): June 30, December 31, 2019 2018 Prepaid clinical trial expenses $ 435 $ 5 Equity issuance costs 343 - Prepaid insurance 670 - Other prepaid expenses 174 5 Total prepaid and other current assets $ 1,622 $ 10 Accrued liabilities consist of the following (in thousands): June 30, December 31, 2019 2018 Payroll and related expenses $ 508 $ 241 Accrued term loan final payment 569 421 Accrued clinical trial expense 8 - Professional fees and other costs 395 195 Total accrued liabilities $ 1,480 $ 857

Note 6 - Term Loans and Convert

Note 6 - Term Loans and Convertible Promissory Notes	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6. Term Loans On November 24, 2015, $3.0 $2.0 11,829 Note 9 7.06% 30 0.19%. The Term Loan A was recorded at its initial carrying value of $3.0 $141,000, $2.0 $3,000. At June 30, 2019, $1.4 $1.0 December 31, 2018, $2.3 $1.5 The following modifications have been made during the six June 30, 2019: ● In January 2019, two eight February 1, 2019 $20.0 $200,000 March 31, 2019 March 31, 2019. $200,000 June 30, 2019. $50,000. ● In May 2019, ● In June 2019, two two January 1, 2020. $20,000. Upon the respective dates of the debt modifications, no Interest expense associated with the Term Loans was $157,000 $171,000 three June 30, 2019 2018, $336,000 $309,000 six June 30, 2019 2018, As of June 30, 2019, Principal payments for the Term Loans due under the Loan Agreement as of June 30, 2019 September 1, 2019 January 1, 2020. Convertible Promissory Notes The table below reflects the principal amount of the Notes issued by the Company (in thousands): June 30, December 31, 2019 2018 Convertible note payable, due on March 29, 2019 $ - $ 1,500 Convertible note payable, due on September 27, 2019 - 1,500 Convertible note payable, due on December 21, 2019 1,500 1,500 Convertible note payable, due on March 29, 2020 1,500 - Convertible note payable, due on April 26, 2020 2,000 - Convertible note payable, due on May 29, 2020 500 - Total $ 5,500 $ 4,500 Outstanding Notes The Notes outstanding at June 30, 2019 (a) in the event that the Company issues and sells equity securities with proceeds to the Company of at least $5 (b) if the Company consummates a change of control while the Notes remain outstanding, the Company shall repay the holders in cash in an amount equal to 200% In April 2019 May 2019, $2.0 $0.5 8% April 26, 2020 May 29, 2020, Converted Notes In May 2019, two $3.2 367,041 In connection with a previous modification, the Company had computed a contingent BCF that was contingent upon the occurrence of a reverse merger. In accordance with ASC 470 20 25 6, not $2.1 three six June 30, 2019. Derivative Liability The Company evaluated its outstanding Notes and determined that certain embedded components relating to conversion and redemption features of those contracts qualified as derivatives, which need to be separately accounted for in accordance with ASC 815. no As of June 30, 2019, no zero zero June 30, 2019. December 31, 2018

Note 7 - Leases

Note 7 - Leases	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 7. The Company leases office facilities under a non-cancelable operating lease agreement expiring on December 31, 2019. 2023. February 1, 2019, April 20, 2023 Future minimum payments under non-cancellable leases as of June 30, 2019 Period ending December 31 Future Commitments 2019 (remaining 6 months) $ 232 2020 227 2021 232 2022 236 2023 80 Total future minimum lease payments 1,007 Less: imputed interest (167 ) Total $ 840 Total operating lease expenses for the three six June 30, 2019 $98,000 $165,000, three six June 30, 2018 $58,000 $115,000, As of June 30, 2019, no June 30, 2019, not not During the three six June 30, 2019, $42,000

Note 8 - Redeemable Convertible

Note 8 - Redeemable Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	Note 8. At December 31, 2018, 2,034,548 1,833,387 2019, 367,041 ‘Note 6 Upon the consummation of the Merger, all outstanding shares of Series A and Series B convertible preferred stock were cancelled and exchanged for shares of the Company’s common stock. Following the Merger, Private Adynxx survived as a wholly-owned subsidiary of new Adynxx, Inc. and adopted a new certificate of incorporation with no 1,000,000

Note 9 - Warrants

Note 9 - Warrants	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Warrants Disclosure [Text Block]	Note 9. Private Adynxx had issued warrants that were previously classified as a liability as they were exercisable for preferred shares that were potentially redeemable. The fair value of the warrant liability was re-measured at each balance sheet date up through the date of the Merger with the change as other income recorded in the statements of operations. On May 3, 2019, not 11,829 $6.34 $234,000 2025 2026. Additionally, upon the closing of the Merger on May 3, 2019, 38,945 $26.40 $28.20 2022.

Note 10 - Stock Options

Note 10 - Stock Options	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 10. On May 3, 2019, 690,058 $1.11 $3.06 Additionally, at the date of the Merger, Alliqua had outstanding employee options to purchase an aggregate of 57,822 $21.00 $656.40 A summary of the Company’s stock option activity during the six June 30, 2019 Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2018 690 $ 2.76 Alliqua options assumed in Merger 58 289.76 Exercised - - Cancelled - - Outstanding, June 30, 2019 748 $ 24.95 6.2 $ 188 Exercisable, June 30, 2019 530 $ 33.93 5.7 $ 188 A summary of the Company’s stock options as of June 30, 2019 Options Outstanding Options Exercisable Weighted Weighted Weighted Range of Average Outstanding Average Average Exercisable Exercise Exercise Number of Exercise Remaining Life Number of Price Price Options Price In Years Options $1.11 - $1.38 $ 1.11 73 $ 1.11 2.5 73 1.39 - 3.05 1.39 37 1.39 3.2 37 3.06 - 20.99 3.06 580 3.06 7.5 362 21.00 - 656.40 289.81 58 289.81 0.7 58 $ 24.95 748 $ 24.95 5.7 530 The Company did not three six June 30, 2019. $68,000 $75,000 three June 30, 2019 2018, $136,000 $150,000 six June 30, 2019 2018, June 30, 2019, $395,000, 1.5 Stock-based compensation expense recorded in exchange for services related to non-employee options was $16,000 $0 three June 30, 2019 2018, $32,000 $0 six June 30, 2019 2018, June 30, 2019, $16,000, three

Note 11 - Related-party Transac

Note 11 - Related-party Transactions	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 11. At June 30, 2019, $5.5 Note 6 – Term Loans and Convertible Promissory Notes’ In connection with the Merger, Alliqua’s existing CEO resigned from the company and received severance pay of $1,091,000. no three six June 30, 2019.

Note 12 - Subsequent Events

Note 12 - Subsequent Events	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 12. In July 2019, $600,000 8% one On August 1, 2019 August 2, 2019, 1 2 1 10, not not

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses incurred during the reporting period. Actual results could differ from those estimates and such differences could be material to the Company’s financial position and results of operations. Significant estimates and assumptions include the valuation of equity instruments and equity-linked instruments, including the valuation of the Company’s common stock and the valuation of the Company’s common stock options for purposes of accounting for stock-based compensation, and accruals for clinical trials and the valuation allowances on deferred tax assets.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Cash and cash equivalents are deposited in demand and money market accounts with established financial institutions and, at times, such balances with any one may not The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company's future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company's products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company's ability to attract and retain employees necessary to support its growth. The Company’s postoperative pain reduction product candidate, brivoligide, is an oligonucleotide. The Company currently uses Nitto-Denko Avecia, Inc. (“Avecia”) as a single supplier for the brivoligide drug substance. There are currently a limited number of oligonucleotide manufacturers with commercial scale capabilities globally. While the Company intends to develop secondary sources for manufacturing of its drug candidates in the future, there can be no June 30, 2019, not At June 30, 2019, three 26%, 22% 17% 44% December 31, 2018, three 52%, 26% 15% 67%
Clinical Trial Accruals, Policy [Policy Text Block]	Clinical Trial Accruals The Company’s clinical trial accruals are based on patient enrollment and related costs at clinical investigator sites as well as for the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical trials on the Company’s behalf. The Company accrues expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity according to the clinical trial protocol. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, the Company modifies the estimates of accrued expenses accordingly. To date, the Company has had no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with a maturity of three
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using a straight-line method over the estimated useful lives of the assets, generally three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not June 30, 2019 December 31, 2018, not
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash At June 30, 2019, $200,000 January 2019. June 30, 2019 December 31, 2018, $55,000
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as they occur. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term— Expected Volatility— Expected Dividend— no Risk-Free Interest Rate— zero
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, preclinical studies, clinical studies performed by contract research organizations (“CROs”), materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. The Company charges research and development costs, including clinical study costs, to expense when incurred.
Collaborative Arrangement, Accounting Policy [Policy Text Block]	Collaboration Agreement In June 2018, May 2019, $75,000, three six June 30, 2019. In June 2019,
Grant Reimbursement, Policy [Policy Text Block]	Grant Reimbursements In December 2018, two December 2020 $5.7 On January 1, 2019, 2018 08, may not For the three six June 30, 2019, $1,104,000 $1,198,000
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance, which would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company's tax return.
Convertible Preferred Stock Warrants, Policy [Policy Text Block]	Convertible Preferred Stock Warrants At December 31, 2018, no $234,000 three six June 30, 2019.
Debt Modifications and Extinguishments, Policy [Policy Text Block]	Debt Modifications and Extinguishments When the Company modifies debt, it does so in accordance with Accounting Standards Codification (“ASC”) 470 50, Debt: Modifications and Extinguishments October 2018 March 2018 September 2018 $11,000 October 2018. not
Derivatives, Policy [Policy Text Block]	Derivative Instruments ASC 815 15, Derivatives and Hedging: Embedded Derivatives three three not not 815. At June 30, 2019 December 31, 2018, 1 2 These embedded features were not As of June 30, 2019 December 31, 2018, no ‘Note 6
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC 820 10, Fair Value Measurement three may Level 1— Level 2— 1 Level 3— This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. The following table presents the Company’s fair value hierarchy for its warrant liability measured at fair value on a recurring basis at December 31, 2018 ( As of December 31, 2018 Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ - $ - $ 140 $ 140 Total financial liabilities $ - $ - $ 140 $ 140 The Level 3 December 31, 2018 December 31, 2018, no three six June 30, 2019. The change in fair value of the warrant liability for the three six June 30, 2019 2018 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ 234 $ 42 $ 140 $ 42 Change in fair value of preferred stock warrants - - 94 - Exchange of warrants upon Merger (234 ) - (234 ) - Fair value at end of period $ - $ 42 $ - $ 42 The carrying amounts reported in the accompanying balance sheets for cash and cash equivalents, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the Company’s term loan is based on the borrowing rate currently available to the Company for borrowings with similar terms and maturity and approximates its carrying value. Derivative liability instruments are considered Level 3 one 3 no While the Company’s Notes contain embedded derivative liabilities, the Company determined that the fair value of these liabilities were zero June 30, 2019 December 31, 2018. Note 6 The change in fair value of the derivative liability relating to the Notes for the three six June 30, 2019 2018 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ - $ 496 $ - $ - Embedded derivative liability from the issuance of Notes - - - 496 Change in value of embedded derivatives - (60 ) - (60 ) Fair value at end of period $ - $ 436 $ - $ 436
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations Discontinued operations represent the activities of the AquaMed business between the date of the Merger and the date of the spin-off. See ‘ Note 3 no June 30, 2019.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements Lease Accounting In February 2016, No. 2016 02, 842 2016 02” 2016 02 twelve 2016 02 December 15, 2018 may 1 2 January 1, 2019 not The Company has elected the package of practical expedients permitted in ASC Topic 842. 842, 842, 842 The most significant impact from the adoption of this standard was the recognition of right-of-use, or ROU, assets and lease obligations on the balance sheet for operating leases. This standard did not January 1, 2019 $227,000, $239,000, 9.41%, $227,000 $227,000. twelve January 1, 2019. Recent Accounting Pronouncements Not In August 2018, No. 2018 13, 820 December 15, 2019, In August 2018, 2018 15, 350 40 2018 15” not January 1, 2020

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of December 31, 2018 Level 1 Level 2 Level 3 Total Financial liabilities Warrant liability $ - $ - $ 140 $ 140 Total financial liabilities $ - $ - $ 140 $ 140
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ 234 $ 42 $ 140 $ 42 Change in fair value of preferred stock warrants - - 94 - Exchange of warrants upon Merger (234 ) - (234 ) - Fair value at end of period $ - $ 42 $ - $ 42 Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 Fair value, beginning of period $ - $ 496 $ - $ - Embedded derivative liability from the issuance of Notes - - - 496 Change in value of embedded derivatives - (60 ) - (60 ) Fair value at end of period $ - $ 436 $ - $ 436

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, December 31, 2019 2018 Furniture and fixtures $ 29 $ 29 Office equipment 2 2 Computer equipment 18 18 Laboratory equipment 2 2 Total property and equipment 51 51 Less accumulated depreciation (45 ) (41 ) Property and equipment, net $ 6 $ 10

Note 5 - Other Balance Sheet _2

Note 5 - Other Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Prepaid and Other Current Assets [Table Text Block]	June 30, December 31, 2019 2018 Prepaid clinical trial expenses $ 435 $ 5 Equity issuance costs 343 - Prepaid insurance 670 - Other prepaid expenses 174 5 Total prepaid and other current assets $ 1,622 $ 10
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2019 2018 Payroll and related expenses $ 508 $ 241 Accrued term loan final payment 569 421 Accrued clinical trial expense 8 - Professional fees and other costs 395 195 Total accrued liabilities $ 1,480 $ 857

Note 6 - Term Loans and Conve_2

Note 6 - Term Loans and Convertible Promissory Notes (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Convertible Debt [Table Text Block]	June 30, December 31, 2019 2018 Convertible note payable, due on March 29, 2019 $ - $ 1,500 Convertible note payable, due on September 27, 2019 - 1,500 Convertible note payable, due on December 21, 2019 1,500 1,500 Convertible note payable, due on March 29, 2020 1,500 - Convertible note payable, due on April 26, 2020 2,000 - Convertible note payable, due on May 29, 2020 500 - Total $ 5,500 $ 4,500

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Period ending December 31 Future Commitments 2019 (remaining 6 months) $ 232 2020 227 2021 232 2022 236 2023 80 Total future minimum lease payments 1,007 Less: imputed interest (167 ) Total $ 840

Note 10 - Stock Options (Tables

Note 10 - Stock Options (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2018 690 $ 2.76 Alliqua options assumed in Merger 58 289.76 Exercised - - Cancelled - - Outstanding, June 30, 2019 748 $ 24.95 6.2 $ 188 Exercisable, June 30, 2019 530 $ 33.93 5.7 $ 188
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Weighted Weighted Range of Average Outstanding Average Average Exercisable Exercise Exercise Number of Exercise Remaining Life Number of Price Price Options Price In Years Options $1.11 - $1.38 $ 1.11 73 $ 1.11 2.5 73 1.39 - 3.05 1.39 37 1.39 3.2 37 3.06 - 20.99 3.06 580 3.06 7.5 362 21.00 - 656.40 289.81 58 289.81 0.7 58 $ 24.95 748 $ 24.95 5.7 530

Note 1 - Organization and Bas_2

Note 1 - Organization and Basis of Presentation (Details Textual)	May 31, 2019USD ($)	May 03, 2019	May 31, 2019USD ($)	Apr. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Dec. 31, 2018USD ($)
Cash and Cash Equivalents, at Carrying Value, Ending Balance					$ 24,000	$ 1,887,000
Retained Earnings (Accumulated Deficit), Ending Balance					(44,417,000)	$ (37,279,000)
Majority Investors [Member] | First Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total				$ 2,000,000
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total	$ 500,000		$ 500,000
Majority Investors [Member] | Notes to Fund the Company's Operations [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%		8.00%
Convertible Debt [Member]
Notes Payable, Total					5,600,000
Oxford Finance, LLC [Member]
Loans Payable, Total					$ 3,000,000
Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		6
Alliqua Biomedical, Inc. [Member]
Business Acquisition, Exchange Ratio		0.0359

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Oct. 31, 2018	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Jan. 01, 2019
Impairment of Long-Lived Assets Held-for-use			$ 0	$ 0
Payments of Dividends, Total			0
Grant Reimbursements		$ 1,104,000	1,198,000
Reclassification of Warrant into Equity		234,000	234,000
Gain (Loss) on Extinguishment of Debt, Total	$ 11,000
Operating Lease, Liability, Total		840,000	840,000
Lessee, Operating Lease, Liability, Payments, Due, Total		1,007,000	1,007,000
Operating Lease, Right-of-Use Asset		779,000	779,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total					$ 227,000
Lessee, Operating Lease, Liability, Payments, Due, Total					$ 239,000
Lessee, Operating Lease, Discount Rate					9.41%
Operating Lease, Right-of-Use Asset					$ 227,000
Modified March 2018 and Modified September 2018 Notes [Member]
Embedded Derivative, Fair Value of Embedded Derivative Asset		0	0	0
Embedded Derivative, Fair Value of Embedded Derivative Liability		0	0	0
Research and Development Expense [Member]
Collaboration Initiation Payment		75,000	75,000
Money Market Funds [Member]
Restricted Cash, Total		200,000	200,000
Letter of Credit 1 [Member]
Restricted Cash, Total		$ 55,000	$ 55,000	55,000
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Grants Receivable				$ 5,700,000
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]
Concentration Risk, Percentage			26.00%	52.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]
Concentration Risk, Percentage			22.00%	26.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Vendor 3 [Member]
Concentration Risk, Percentage			17.00%	15.00%
Accounts Payable 1 [Member] | Supplier Concentration Risk [Member] | Two of the Three Vendors Supporting Clinical Study Activities [Member]
Concentration Risk, Percentage			44.00%	67.00%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Fair Value Measurements Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Warrant liability		$ 140
Fair Value, Recurring [Member]
Total financial liabilities		140
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Total financial liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Total financial liabilities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Total financial liabilities		140
Warrant [Member] | Fair Value, Recurring [Member]
Warrant liability		140
Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Warrant liability
Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Warrant liability
Warrant [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Warrant liability		$ 140

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Change in Fair Value of Preferred Stock Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Derivative [Member]
Fair value, beginning of period		$ 496
Change in value		(60)		(60)
Embedded derivative liability from the issuance of Notes				496
Fair value at end of period		436		436
Warrant [Member]
Fair value, beginning of period	234	42	140	42
Change in value			94
Exchange of warrants upon Merger	(234)		(234)
Fair value at end of period		$ 42		$ 42

Note 3 - Reverse Merger (Detail

Note 3 - Reverse Merger (Details Textual)	May 29, 2019USD ($)$ / shares	May 03, 2019USD ($)shares	May 31, 2019shares	Jun. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 21, 2019$ / shares
Number of Shares Held by Equity Holders | shares		4,936,784
Interest Expense [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature				$ 2,100,000	$ 2,100,000
Alliqua Biomedical, Inc. [Member]
Dividends, Total	$ 5,245,000
Common Stock, Dividends, Per Share, Cash Paid | $ / shares	$ 1.05
AquaMed [Member]
Common Stock, Stock Dividends, Per Share, Book Value | $ / shares						$ 0.01
Reverse Stock Split From [Member] | Alliqua Biomedical, Inc. [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		6
Alliqua Biomedical, Inc. [Member]
Business Acquisition, Exchange Ratio		0.0359
Intangible Assets, Net (Including Goodwill), Total		$ 0
Merger Agreement, Percentage Ownership in Combined Company, Acquirer		86.00%
Merger Agreement, Percentage Ownership in Combined Company, Acquiree		14.00%
Alliqua Biomedical, Inc. [Member] | Conversion of Notes into Series B Convertible Preferred Stock [Member]
Debt Conversion, Original Debt, Amount, Principal		$ 3,000,000
Debt Conversion, Original Debt, Amount, Cumulative Accrued Interest		$ 203,000
Debt Conversion, Converted Instrument, Shares Issued | shares		367,041	367,041
Debt Instrument, Convertible, Beneficial Conversion Feature				$ 2,100,000

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Depreciation, Total	$ 2,000	$ 2,000	$ 4,000	$ 4,000

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property and equipment, gross	$ 51	$ 51
Less accumulated depreciation	(45)	(41)
Property and equipment, net	6	10
Furniture and Fixtures [Member]
Property and equipment, gross	29	29
Office Equipment [Member]
Property and equipment, gross	2	2
Computer Equipment [Member]
Property and equipment, gross	18	18
Laboratory Equipment [Member]
Property and equipment, gross	$ 2	$ 2

Note 5 - Other Balance Sheet _3

Note 5 - Other Balance Sheet Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepaid clinical trial expenses	$ 435	$ 5
Equity issuance costs	343
Prepaid insurance	670
Other prepaid expenses	174	5
Total prepaid and other current assets	$ 1,622	$ 10

Note 5 - Other Balance Sheet _4

Note 5 - Other Balance Sheet Information - Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Payroll and related expenses	$ 508	$ 241
Accrued term loan final payment	569	421
Accrued clinical trial expense	8
Professional fees and other costs	395	195
Total accrued liabilities	$ 1,480	$ 857

Note 6 - Term Loans and Conve_3

Note 6 - Term Loans and Convertible Promissory Notes (Details Textual) - USD ($)	May 31, 2019	May 03, 2019	Nov. 24, 2015	Jun. 30, 2019	May 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 20, 2019	Dec. 31, 2018	Oct. 31, 2018
Beneficial Conversion Feature, Conversion of Convertible Note
Conversion of Notes into Series B Convertible Preferred Stock [Member]
Debt Conversion, Original Debt, Amount					$ 3,200,000
Conversion of Notes into Series B Convertible Preferred Stock [Member] | Alliqua Biomedical, Inc. [Member]
Debt Conversion, Converted Instrument, Shares Issued		367,041			367,041
Debt Instrument, Convertible, Beneficial Conversion Feature									$ 2,100,000
Beneficial Conversion Feature, Conversion of Convertible Note											$ 2,100,000
Modified March 2019 and Modified December 2018 Notes [Member]
Debt Instrument, Convertible, Preferred Stock Proceeds Trigger											$ 5,000,000
Debt Instrument, Conversion to Cash in Case of Change in Control				200.00%					200.00%		200.00%		200.00%
Modified March 2018, September 2018, December 2018, and March 2019 Notes [Member]
Probability of Qualified Financing Occurring																0.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability				$ 0					$ 0		$ 0		$ 0
Probability of Change in Control Occurring																0.00%
Warrant to Purchase Series A Convertible Preferred Stock Under Oxford Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			11,829
Oxford Finance, LLC [Member] | Term Loan A [Member]
Debt Instrument, Face Amount			$ 3,000,000
Proceeds from Issuance of Debt			3,000,000
Debt Issuance Costs, Gross			141,000
Loans Payable, Total				1,400,000					1,400,000		1,400,000		1,400,000		$ 2,300,000
Oxford Finance, LLC [Member] | Term Loan B [Member]
Debt Instrument, Face Amount			$ 2,000,000
Proceeds from Issuance of Debt													2,000,000
Debt Issuance Costs, Gross				3,000					3,000		3,000		3,000
Loans Payable, Total				$ 1,000,000					1,000,000		1,000,000		1,000,000		$ 1,500,000
Oxford Finance, LLC [Member] | Term Loans [Member]
Debt Instrument, Interest Rate, Stated Percentage			7.06%
Debt Instrument, Periodic Payment, Increase (Decrease) of Interest-Only Payments				60 days
Gain (Loss) Debt Modification				$ 0	$ 0		$ 0
Interest Expense, Debt, Total									157,000	$ 171,000	336,000	$ 309,000
Oxford Finance, LLC [Member] | Term Loans [Member] | Domain [Member]
Debt Instrument, Increase of Periodic Payments Upon Delivery of Executed Term Sheet							240 days
Proceeds from Noncontrolling Interests							$ 20,000,000
Restricted Cash, Total				$ 200,000					$ 200,000		$ 200,000		$ 200,000
Debt Instrument, Periodic Payment Terms, Increase (Decrease) in Balloon Payment to be Paid							$ 50,000							$ 20,000
Oxford Finance, LLC [Member] | Term Loans [Member] | Convertible Promissory Note of 1.5 Million [Member]
Debt Instrument, Increase of Interest-Only Periodic Payments Upon Entering Into a Merger								60 days
Oxford Finance, LLC [Member] | Term Loans [Member] | London Interbank Offered Rate (LIBOR) Swap Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate			0.19%
Majority Investors [Member] | First Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total						$ 2,000,000
Majority Investors [Member] | Second Note to Fund the Company's Operations [Member]
Proceeds from Notes Payable, Total	$ 500,000				$ 500,000
Majority Investors [Member] | Notes to Fund the Company's Operations [Member]
Debt Instrument, Interest Rate, Stated Percentage	8.00%				8.00%

Note 6 - Term Loans and Conve_4

Note 6 - Term Loans and Convertible Promissory Notes - Convertible Promissory Notes (Details) - USD ($) $ in Millions	Jun. 30, 2019	Dec. 31, 2018
Convertible note payable, due on March 29, 2019	$ 5.5	$ 4.5
Convertible Note Payable, One [Member]
Convertible note payable, due on March 29, 2019		1.5
Convertible Note Payable Two [Member]
Convertible note payable, due on March 29, 2019		1.5
Convertible Note Payable, Three [Member]
Convertible note payable, due on March 29, 2019	1.5	1.5
Convertible Note Payable, Four [Member]
Convertible note payable, due on March 29, 2019	1.5
Convertible Note Payable Five [Member]
Convertible note payable, due on March 29, 2019	2
Convertible Note Payable Six [Member]
Convertible note payable, due on March 29, 2019	$ 0.5

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) xbrli-pure in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
Operating Lease, Expense	$ 98,000		$ 165,000
Operating Leases, Rent Expense, Total		$ 58,000		$ 115,000
Finance Lease, Liability, Total	$ 0		$ 0
Lessee, Operating Lease, Not yet Commenced	0		0
Lessee, Finance Lease, Not yet Commenced	0		0
Sublease Income	$ 42,000		$ 42,000

Note 7 - Leases - Future Minimu

Note 7 - Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2019USD ($)
2019 (remaining 6 months)	$ 232
2020	227
2021	232
2022	236
2023	80
Total future minimum lease payments	1,007
Less: imputed interest	(167)
Total	$ 840

Note 8 - Redeemable Convertib_2

Note 8 - Redeemable Convertible Preferred Stock (Details Textual) - shares	1 Months Ended
	May 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Preferred Stock, Shares Issued, Total		0	0
Preferred Stock, Shares Authorized		1,000,000	1,000,000
Preferred Stock, Shares Outstanding, Ending Balance		0	0
Conversion of Notes into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	367,041
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Issued			2,034,548
Temporary Equity, Shares Outstanding		0	2,034,548
Series B Redeemable Convertible Preferred Stock [Member]
Temporary Equity, Shares Issued			1,833,387
Temporary Equity, Shares Outstanding		0	1,833,387

Note 9 - Warrants (Details Text

Note 9 - Warrants (Details Textual) - USD ($)	May 03, 2019	Jun. 30, 2019
Exchange of Warrants Upon Merger		$ 234,000
Alliqua Warrants Assumed in Merger [Member]
Class of Warrant or Right, Outstanding	38,945
Alliqua Warrants Assumed in Merger [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 26.40
Alliqua Warrants Assumed in Merger [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 28.20
Alliqua Biomedical, Inc. [Member] | Warrant to Purchase Common Stock Converted in Merger [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	11,829
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.34
Exchange of Warrants Upon Merger	$ 234,000

Note 10 - Stock Options (Detail

Note 10 - Stock Options (Details Textual) - USD ($)	May 03, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		748,000		748,000		690,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		0		0
Share-based Payment Arrangement, Expense		$ 68,000	$ 75,000	$ 136,000	$ 150,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		395,000		$ 395,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				1 year 182 days
Non-employee Options [Member]
Share-based Payment Arrangement, Expense		$ 16,000	$ 0	$ 32,000	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition				90 days
Non-employee Stock Options, Comensation Expense, Cost Not yet Recognized, Period for Recognition				16000 years
Alliqua Biomedical, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	57,822
Minimum [Member] | Alliqua Biomedical, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price	$ 21
Maximum [Member] | Alliqua Biomedical, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price	$ 656.40
Alliqua Biomedical, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	690,058
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance		58,000		58,000
Alliqua Biomedical, Inc. [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price	$ 1.11
Alliqua Biomedical, Inc. [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price	$ 3.06

Note 10 - Stock Options - Summa

Note 10 - Stock Options - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Number of Options, outstanding (in shares)	690
Weighted Average Exercise Price, outstanding (in dollars per share)	$ 2.76
Number of Options, Alliqua options assumed in merger (in shares)	690	748
Weighted Average Exercise Price, Alliqua options assumed in merger (in dollars per share)	$ 2.76	$ 24.95
Number of Options, exercised (in shares)
Weighted Average Exercise Price, exercised (in dollars per share)
Number of Options, cancelled (in shares)
Weighted Average Exercise Price, cancelled (in dollars per share)
Number of Options, outstanding (in shares)	748
Weighted Average Exercise Price, outstanding (in dollars per share)	$ 24.95
Weighted Average Remaining Life in Years, outstanding (Year)	6 years 73 days
Intrinsic Value, outstanding		$ 188
Number of Options, exercisable (in shares)		530
Weighted Average Exercise Price, exercisable (in dollars per share)		$ 33.93
Weighted Average Remaining Life in Years, exercisable (Year)	5 years 255 days
Intrinsic Value, exercisable		$ 188
Alliqua Biomedical, Inc. [Member]
Number of Options, Alliqua options assumed in merger (in shares)	58	58
Weighted Average Exercise Price, Alliqua options assumed in merger (in dollars per share)	$ 289.76	$ 289.76
Number of Options, outstanding (in shares)	58
Weighted Average Exercise Price, outstanding (in dollars per share)	$ 289.76

Note 10 - Stock Options - Stock

Note 10 - Stock Options - Stock Options by Exercise Price Range (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Options Outstanding, weighted average exercise price (in dollars per share)	$ 24.95
Options Outstanding, number of options (in shares) | shares	748
Options Exercisable, weighted average exercise price (in dollars per share)	$ 24.95
Options Exercisable, weighted average remaining life in years (Year)	5 years 255 days
Options exercisable, number of options exercisable (in shares) | shares	530
Price Range 1 [Member]
Range of Exercise Price, lower (in dollars per share)	$ 1.11
Range of Exercise Price, upper (in dollars per share)	1.38
Options Outstanding, weighted average exercise price (in dollars per share)	$ 1.11
Options Outstanding, number of options (in shares) | shares	73
Options Exercisable, weighted average exercise price (in dollars per share)	$ 1.11
Options Exercisable, weighted average remaining life in years (Year)	2 years 182 days
Options exercisable, number of options exercisable (in shares) | shares	73
Price Range 2 [Member]
Range of Exercise Price, lower (in dollars per share)	$ 1.39
Range of Exercise Price, upper (in dollars per share)	3.05
Options Outstanding, weighted average exercise price (in dollars per share)	$ 1.39
Options Outstanding, number of options (in shares) | shares	37
Options Exercisable, weighted average exercise price (in dollars per share)	$ 1.39
Options Exercisable, weighted average remaining life in years (Year)	3 years 73 days
Options exercisable, number of options exercisable (in shares) | shares	37
Price Range 3 [Member]
Range of Exercise Price, lower (in dollars per share)	$ 3.06
Range of Exercise Price, upper (in dollars per share)	20.99
Options Outstanding, weighted average exercise price (in dollars per share)	$ 3.06
Options Outstanding, number of options (in shares) | shares	580
Options Exercisable, weighted average exercise price (in dollars per share)	$ 3.06
Options Exercisable, weighted average remaining life in years (Year)	7 years 182 days
Options exercisable, number of options exercisable (in shares) | shares	362
Price Range 4 [Member]
Range of Exercise Price, lower (in dollars per share)	$ 21
Range of Exercise Price, upper (in dollars per share)	656.40
Options Outstanding, weighted average exercise price (in dollars per share)	$ 289.81
Options Outstanding, number of options (in shares) | shares	58
Options Exercisable, weighted average exercise price (in dollars per share)	$ 289.81
Options Exercisable, weighted average remaining life in years (Year)	255 days
Options exercisable, number of options exercisable (in shares) | shares	58

Note 11 - Related-party Trans_2

Note 11 - Related-party Transactions (Details Textual) - USD ($)	May 03, 2019	Jun. 30, 2019
Chief Executive Officer [Member] | Severance Pay [Member]
Related Party Transaction, Amounts of Transaction	$ 1,091,000
Majority Investors [Member]
Notes Payable, Related Parties		$ 5,500,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual)	Aug. 02, 2019	Aug. 01, 2019	Jul. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
Proceeds from Related Party Debt				$ 3,996,000	$ 1,500,000
Subsequent Event [Member] | Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	2	2
Subsequent Event [Member] | Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10	10
Domain [Member] | Subsequent Event [Member]
Proceeds from Related Party Debt			$ 600,000
Debt Instrument, Interest Rate, Stated Percentage			8.00%